Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 839 | 216.1 |
09:38 ET | 300 | 213.87 |
09:39 ET | 5800 | 215.89 |
09:41 ET | 225 | 215.89 |
09:43 ET | 100 | 214.805 |
09:48 ET | 285 | 212.973 |
09:50 ET | 500 | 216.2399 |
09:52 ET | 500 | 214.225 |
09:56 ET | 335 | 214.87 |
10:01 ET | 100 | 214.995 |
10:03 ET | 203 | 215.33 |
10:06 ET | 100 | 215.245 |
10:08 ET | 101 | 215.245 |
10:12 ET | 200 | 215.67 |
10:14 ET | 300 | 215.34 |
10:15 ET | 100 | 215.14 |
10:17 ET | 500 | 215.195 |
10:19 ET | 125 | 215.2925 |
10:21 ET | 100 | 215.12 |
10:24 ET | 400 | 216.3099 |
10:26 ET | 381 | 216.1 |
10:30 ET | 200 | 216.31 |
10:32 ET | 1028 | 215.54 |
10:33 ET | 100 | 215.345 |
10:39 ET | 100 | 215.58 |
10:44 ET | 715 | 215.8 |
10:48 ET | 500 | 215.955 |
10:50 ET | 300 | 215.965 |
10:53 ET | 200 | 215.705 |
10:57 ET | 200 | 215.57 |
11:02 ET | 200 | 215.76 |
11:04 ET | 100 | 215 |
11:09 ET | 100 | 214.94 |
11:11 ET | 480 | 215.29 |
11:18 ET | 5800 | 215.79 |
11:20 ET | 500 | 215.735 |
11:22 ET | 300 | 215.22 |
11:24 ET | 1400 | 214.99 |
11:26 ET | 300 | 214.81 |
11:27 ET | 200 | 215.07 |
11:31 ET | 200 | 215.435 |
11:33 ET | 1000 | 215.585 |
11:36 ET | 500 | 216.055 |
11:38 ET | 322 | 215.6 |
11:47 ET | 200 | 215.58 |
11:49 ET | 400 | 215.6 |
11:54 ET | 100 | 215.49 |
11:56 ET | 322 | 215.64 |
11:58 ET | 222 | 216.09 |
12:00 ET | 222 | 216.09 |
12:02 ET | 2050 | 215.455 |
12:03 ET | 100 | 215.33 |
12:05 ET | 200 | 215.2153 |
12:12 ET | 1278 | 214.99 |
12:16 ET | 300 | 214.81 |
12:18 ET | 700 | 214.905 |
12:21 ET | 184 | 215.09 |
12:25 ET | 100 | 214.93 |
12:27 ET | 1500 | 214.94 |
12:30 ET | 100 | 214.955 |
12:32 ET | 163 | 214.97 |
12:36 ET | 11490 | 215.1 |
12:38 ET | 300 | 215.21 |
12:43 ET | 279 | 215.4935 |
12:45 ET | 100 | 215.255 |
12:50 ET | 510 | 214.9 |
12:52 ET | 100 | 215.005 |
01:01 ET | 300 | 215.22 |
01:08 ET | 134 | 215.25 |
01:10 ET | 100 | 214.84 |
01:12 ET | 324 | 214.985 |
01:14 ET | 1453 | 215.135 |
01:15 ET | 580 | 215.2284 |
01:17 ET | 359 | 215.2 |
01:19 ET | 598 | 214.6 |
01:21 ET | 883 | 215.01 |
01:28 ET | 100 | 215.095 |
01:30 ET | 521 | 215.465 |
01:37 ET | 386 | 215.375 |
01:39 ET | 136 | 215.295 |
01:42 ET | 100 | 215.52 |
01:48 ET | 2947 | 215.5 |
01:50 ET | 9080 | 215.58 |
01:51 ET | 2020 | 215.36 |
01:53 ET | 500 | 215.5 |
01:55 ET | 300 | 215.5 |
01:57 ET | 100 | 215.26 |
02:08 ET | 100 | 214.69 |
02:09 ET | 300 | 214.69 |
02:20 ET | 992 | 214.62 |
02:26 ET | 582 | 214.115 |
02:27 ET | 500 | 214.41 |
02:31 ET | 300 | 212.965 |
02:33 ET | 100 | 212.88 |
02:38 ET | 200 | 212.905 |
02:42 ET | 100 | 212.715 |
02:44 ET | 400 | 212.92 |
02:45 ET | 300 | 212.925 |
02:47 ET | 193 | 213.29 |
02:56 ET | 100 | 213.08 |
03:00 ET | 100 | 213.63 |
03:02 ET | 200 | 213.08 |
03:03 ET | 192 | 212.52 |
03:05 ET | 450 | 212.38 |
03:07 ET | 300 | 212.515 |
03:09 ET | 100 | 212.28 |
03:12 ET | 200 | 211.96 |
03:14 ET | 100 | 211.865 |
03:16 ET | 200 | 211.7 |
03:18 ET | 300 | 211.3 |
03:20 ET | 1300 | 211.5822 |
03:21 ET | 6092 | 212.415 |
03:23 ET | 600 | 212.89 |
03:25 ET | 1047 | 212.965 |
03:27 ET | 4000 | 213.73 |
03:30 ET | 6700 | 214.155 |
03:32 ET | 300 | 213.565 |
03:34 ET | 1266 | 213.585 |
03:36 ET | 3100 | 213.015 |
03:38 ET | 1800 | 213.43 |
03:39 ET | 100 | 213.5 |
03:41 ET | 307 | 212.71 |
03:43 ET | 100 | 212.68 |
03:45 ET | 700 | 212.22 |
03:48 ET | 1969 | 213.08 |
03:50 ET | 200 | 213.34 |
03:52 ET | 848 | 213.07 |
03:54 ET | 3393 | 212.7 |
03:56 ET | 6759 | 212.4 |
03:57 ET | 5502 | 212.37 |
03:59 ET | 25130 | 212.43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.3B | -8.3x | --- |
BridgeBio Pharma Inc | 4.9B | -9.5x | --- |
Nuvalent Inc | 5.7B | -35.6x | --- |
Avidity Biosciences Inc | 4.9B | -14.3x | --- |
Krystal Biotech Inc | 5.8B | 48.5x | --- |
Immunovant Inc | 4.3B | -14.6x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.44 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | 358.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.